Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.5852W HIGH $10.10
Volume
356.55 K
Value Traded
3.85 M
Short % Float
11.01%
+4.84%Week
+10.17%1 Month
+24.63%3 Month
+28.15%6 Month
-33.52%5 Year
-29.2%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
514.65 M
EPS (TTM)
0.52
P/E Ratio
19.26
Ent. Value
420.75 M
Total Shares
51.61 M
Float Shares
39.22 M
Insiders
24.02%
Institutions
67.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PBYI Catalyst Timeline
Dated clinical, regulatory and corporate events for Puma Biotechnology Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Puma Biotechnology Inc
254Total events
3Upcoming
89Tier-1 (high impact)
2012 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Equity OfferingCorporate
Compensation Committee approved inducement RSU award covering 7,500 shares to one new non-executive employee
●Trial InitiationAlisertibTrial
Puma initiated ALISCA-Lung2 Phase II trial of alisertib in combination with paclitaxel in advanced small cell lung cancer
advanced small cell lung cancersource ↗
●Quarterly UpdateCorporate
Puma Biotechnology to host conference call to discuss Q2 2026 financial results
◆Timing GuidanceAlisertibPresentation
Initiation of enrollment in ALISCA-Lung2, Phase I/II trial of alisertib plus paclitaxel in extensive stage SCLC
extensive stage small cell lung cancersource ↗
▲Debt Royalty FinancingCorporate
Puma remitted final payment under 2021 Note Purchase Agreement, reducing outstanding debt to zero
◆Oral PresentationAlisertibPresentation
Interim data from ALISCA-Breast1 (alisertib + endocrine therapy) to be presented
HER2-negative, hormone receptor-positive metastatic breast cancersource ↗
◆Oral PresentationPresentation
Puma Biotechnology presentation at TD Cowen 46th Annual Health Care Conference
●Trial InitiationAlisertibTrial
Puma initiated ALISCA-Breast1 Phase II trial of alisertib in combination with endocrine therapy in HER2-negative, HR-positive metastatic breast cancer
HER2-negative, HR-positive metastatic breast cancersource ↗
●Trial InitiationAlisertibTrial
Puma initiated ALISCA-Lung1 Phase II trial of alisertib monotherapy in extensive-stage small cell lung cancer
extensive-stage small cell lung cancersource ↗
▲Partnership / LicenseAlisertibCorporate
Puma entered exclusive license agreement for development and commercialization of alisertib
◆FDA Feedback ReceivedNeratinibApprovedFDA Meeting
Meeting with FDA to discuss accelerated approval pathway for neratinib in NSCLC with EGFR exon 18 mutations
non-small cell lung cancer with EGFR exon 18 mutationssource ↗
◆Topline ReadoutNeratinibApprovedClinical Data
Topline data from randomized cohort of SUMMIT trial in HR+ HER2-mutated breast cancer
hormone receptor positive breast cancer with HER2 mutationsource ↗
◆Pre NDA MeetingNeratinibApprovedFDA Meeting
Pre-NDA meeting with FDA for accelerated approval of neratinib in HER2-mutated HR+ breast cancer
HER2-mutated hormone receptor positive breast cancersource ↗
◆Enrollment CompleteNeratinibApprovedTrial
Complete enrollment in randomized cohort of Phase II SUMMIT trial of neratinib in HR+ HER2-mutated breast cancer
hormone receptor positive breast cancer that has a HER2 mutationsource ↗
▲Enrollment CompleteNeratinibApprovedTrial
Completed enrollment in randomized cohorts of Phase II SUMMIT trial of neratinib for HR+ HER2-mutated breast cancer
hormone receptor-positive breast cancer with HER2 mutationsource ↗
▲Partnership / LicenseNERLYNXApprovedCorporate
Upfront payment from Pierre Fabre for development, manufacturing, and commercial rights to NERLYNX in Greater China
◆Pre NDA MeetingNeratinibApprovedFDA Meeting
Pre-NDA meeting with FDA for accelerated approval of neratinib in HER2 mutated HR+ breast cancer and cervical cancer
HER2 mutated hormone receptor positive breast cancer and HER2 mutated cervical cancersource ↗
◆Topline ReadoutNeratinibApprovedClinical Data
Phase II SUMMIT trial data in bile duct cancer with HER2 mutations
bile duct cancer with HER2 mutationssource ↗
◆FDA Feedback ReceivedNeratinibApprovedFDA Meeting
Conduct meeting with FDA to discuss potential accelerated approval pathway for neratinib in NSCLC with EGFR exon 18 mutations
non-small cell lung cancer patients with EGFR exon 18 mutations previously treated with EGFR TKIsource ↗
◆Other Regulator MilestoneNERLYNXApprovedEx-US Regulatory
Regulatory decisions for extended adjuvant HER2+ early stage breast cancer indication in additional countries
HER2-positive early stage breast cancer (extended adjuvant)source ↗
◆FDA ApprovalNeratinibApprovedFDA Decision
Meeting with FDA to discuss accelerated approval pathway for neratinib in NSCLC with EGFR exon 18 mutations
non-small cell lung cancer with EGFR exon 18 mutations previously treated with EGFR TKIsource ↗
▲Label ExpansionNERLYNXApprovedFDA Decision
FDA label expansion for dose escalation of NERLYNX
HER2-positive early stage and metastatic breast cancersource ↗
◆Topline ReadoutNeratinibApprovedClinical Data
Phase II SUMMIT trial data for neratinib in HER2 mutated HR+ breast cancer
hormone receptor positive breast cancer with HER2 mutationssource ↗
◆Additional DataNeratinibApprovedClinical Data
Report additional data from Phase II CONTROL trial
●Pre NDA MeetingNeratinibApprovedFDA Meeting
Pre-NDA meeting with FDA to discuss accelerated approval of neratinib in HER2 mutated HR+ breast cancer and HER2 mutated cervical cancer
HER2 mutated hormone receptor positive breast cancer and HER2 mutated cervical cancersource ↗
◆Other Regulator MilestoneNERLYNXApprovedEx-US Regulatory
Regulatory decisions for extended adjuvant indication in additional countries
extended adjuvant HER2-positive early stage breast cancersource ↗
▲NMPA NDA ApprovalNERLYNXApprovedEx-US Regulatory
Marketing approval of NERLYNX in mainland China by CANbridge Pharmaceuticals
breast cancersource ↗
◆Timing GuidanceNeratinibApprovedPresentation
U.S. regulatory decision on neratinib in third-line HER2-positive metastatic breast cancer expected
third-line HER2-positive metastatic breast cancersource ↗
◆PDUFA DateNERLYNXApprovedRegulatory Filing
PDUFA date for NERLYNX sNDA (April 2020)
HER2+ metastatic breast cancer (third-line)source ↗
▲FDA ApprovalNERLYNXApprovedFDA Decision
FDA approved NERLYNX in combination with capecitabine for advanced/metastatic HER2-positive breast cancer
in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic settingsource ↗
▲Supplemental ApprovalNERLYNXApprovedFDA Decision
FDA approved NERLYNX plus capecitabine for advanced/metastatic HER2+ breast cancer
advanced or metastatic HER2-positive breast cancer in combination with capecitabinesource ↗
●Oral PresentationPresentation
Puma Biotechnology J.P. Morgan 2020 Healthcare Conference presentation
●Enrollment UpdateNERLYNXApprovedTrial
CONTROL study currently enrolling (as of presentation date)
HER2+ early breast cancersource ↗
●Trial InitiationNERLYNXApprovedTrial
TBCRC-022 Phase II trial of neratinib and capecitabine for brain metastases ongoing
HER2+ breast cancer with brain metastasessource ↗
●Protocol AmendmentNeratinibApprovedTrial
Modify SUMMIT basket trial to expand HER2-mutated breast cancer cohort
HER2-mutated breast cancersource ↗
◆Other Regulator MilestoneNERLYNXApprovedEx-US Regulatory
Regulatory decisions for extended adjuvant HER2-positive early stage breast cancer indication in additional countries
extended adjuvant HER2-positive early stage breast cancersource ↗
◆FDA ApprovalNERLYNXApprovedFDA Decision
Expected regulatory approval in Israel (Q1 2020)
HER2+ early breast cancer (extended adjuvant)source ↗
●Oral PresentationNERLYNXApprovedPresentation
Clinical data presentations at SABCS
HER2-positive breast cancersource ↗
▲FDA ApprovalNERLYNXApprovedFDA Decision
NERLYNX approved in Singapore (November 2019)
HER2+ early breast cancer (extended adjuvant)source ↗
Past FDA Catalysts and PDUFA Decisions
How PBYI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Alisertib | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C47 / 100
Pipeline Score
$485M
Pipeline Value
$536M
Commercial Value
Undervalued
Valuation Signal
2
Drugs Scored
3.3x
rNPV / MCap
Top 25%
Micro Cap(rank 165 of 658)
Percentile Rank
Puma Biotechnology Inc carries a moderate pipeline score (47/100), with $1.2B risk-adjusted pipeline value, led by Alisertib in Small Cell Lung Cancer (Phase 2), across $63B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $231.2M x 2.3 = $536M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| NERLYNX | $207M | $203M | +2.2% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alisertib Small moleculeNCT07465757 | Small Cell Lung Cancer | Phase 2 | RECRUITING | 170 | Sep 30, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every PBYI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PB272 | breast cancer | Phase 3 | 2015-06-01 | primary: hazard ratio 0.67, p value 0.009, two year dfs rate neratinib 93.9%, two year dfs rate placebo 91.6%; secondary: hazard ratio 0.63, p value 0.002, two year dfs dcis rate neratinib 93.9%, two year dfs dcis rate placebo 91.0%Read More | Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free SurvivalRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WILSON TROY EDWARDDirector | Sell | -5,000 54,750 held | $9.10 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PBYI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 % | 1.06 M | 200.00 K |
PBYI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PBYI ranks across every disease it competes in
Competitive Position is a premium feature
See how PBYI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPBYI News
PBYI▲ +1.6%today
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology has announced the grant of an inducement award to a new employee in September 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). This move reflects the company's commitment to growth and adherence to regulatory requirements. The award is part of the company's strategy to attract talent.
Read more →PBYIPuma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Puma Biotechnology has launched the ALISCA®-Lung2 trial, a Phase II study evaluating the efficacy of alisertib combined with paclitaxel for patients suffering from advanced small cell lung cancer. This initiative represents a significant step forward in addressing treatment options for this challenging cancer type.
Read more →PBYIPuma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
Puma Biotechnology's CEO, Alan Auerbach, is scheduled to present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026. This event aims to provide insights into the company's strategies and future directions. The presentation is expected to attract investor attention and foster engagement.
Read more →PBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology has disclosed its inducement awards granted in August 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). This compliance demonstrates the company's commitment to regulatory standards and corporate governance. The inducement awards are likely aimed at enhancing talent acquisition and retention.
Read more →PBYI▲ +9.7%on this news
Puma Biotechnology Reports Second Quarter 2026 Financial Results
Puma Biotechnology announced that it will hold a conference call on August 6, 2026, at 1:30 p.m. PT to discuss its financial results for the second quarter of 2026. This event follows the release of the company's earnings, indicating a commitment to communicate with stakeholders.
Read more →PBYIPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
Puma Biotechnology has announced a conference call to discuss its financial results for the second quarter of 2026. The call is scheduled for August 6, 2026, at 1:30 p.m. PT. This event reflects the company's commitment to keeping stakeholders informed about its financial performance.
Read more →PBYIPuma Biotechnology Reports First Quarter 2026 Financial Results
Puma Biotechnology reported its financial results for Q1 2026, showing a net loss of $3.8 million, down from a net income of $3.0 million in Q1 2025. Despite a slight decrease in product revenue from NERLYNX, the company raised its revenue guidance for 2026, citing increased demand. Additionally, Puma is focusing on expanding clinical trials for alisertib, with promising interim data supporting its development.
Read more →PBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026
Puma Biotechnology announced the approval of inducement restricted stock unit awards for five new non-executive employees on April 1, 2026. The awards, totaling 31,625 shares, will vest over three years as part of the company's strategy to attract new talent. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and supports Puma's ongoing commitment to cancer care innovation.
Read more →PBYI▼ -25%on this news
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
Puma Biotechnology reported its financial results for Q4 and full year 2025, showing a net income of $13.4 million for Q4, down from $19.3 million in Q4 2024. Despite this decline, the company has maintained profitability for three consecutive years. Product revenue from NERLYNX increased, contributing to a total revenue of $75.5 million in Q4 2025. The company anticipates continued profitability into 2026 and has outlined key clinical milestones for its alisertib trials.
Read more →PBYI▲ +5.3%on this news· ran to -20% by day 3shared move
Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference
Puma Biotechnology will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Alan H. Auerbach will provide an overview of the company during the event. The conference will take place at the Boston Marriott Copley Place, and a live webcast will be available on Puma's website.
Read more →PBYIPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - February 4, 2026
Puma Biotechnology announced the approval of inducement restricted stock unit awards for two new non-executive employees. The awards, covering 14,750 shares, will vest over three years and are part of Puma's 2017 Employment Inducement Incentive Award Plan. This move aims to attract talent while adhering to Nasdaq Listing Rule 5635(c)(4).
Read more →PBYIPuma Biotechnology Reports Second Quarter 2021 Financial Results
Puma Biotechnology Reports Second Quarter 2021 Financial Results LOS ANGELES, Calif., Aug. 5, 2021 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2021. Unless otherwise stated, all comparis
Read more →PBYIPuma Biotechnology Reports First Quarter 2021 Financial Results
Puma Biotechnology Reports First Quarter 2021 Financial Results LOS ANGELES, Calif., May 6, 2021 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2021. Unless otherwise stated, all comparison
Read more →PBYIPuma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Biotechnology Reports Fourth Quarter and Full Year Financial Results LOS ANGELES, Calif., Feb. 25, 2021 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2020. Unless otherwise st
Read more →PBYIPuma Biotechnology Reports Third Quarter 2020 Financial Results
Puma Biotechnology Reports Third Quarter 2020 Financial Results LOS ANGELES, Calif., Nov. 5, 2020 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2020. Unless otherwise stated, all compa
Read more →About Puma Biotechnology Inc
Headquarters10880 WILSHIRE BLVD., LOS ANGELES, CA
BIOPHARMAWATCH ELITE PLUS
Trade the next PBYI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime